Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma. - Wikidata - wikimedia - TriplyDB

Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma.

Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma.

http://www.wikidata.org/entity/Q34089534

about

The role of autologous and allogeneic hematopoietic stem cell transplantation for Hodgkin lymphoma High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Tr Allogeneic hematopoietic cell transplantation: the state of the art The Role of Allogeneic Stem Cell Transplantation in Relapsed/Refractory Hodgkin's Lymphoma Patients.Hodgkin's lymphoma therapy: past, present, and future.Relapse of lymphoma after allogeneic hematopoietic cell transplantation: management strategies and outcome.Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma.Alternative donors extend transplantation for patients with lymphoma who lack an HLA matched donor.High-dose cyclophosphamide for graft-versus-host disease prevention.Outcome of patients activating an unrelated donor search: the impact of transplant with reduced intensity conditioning in a large cohort of consecutive high-risk patients.Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma: a systematic review and meta-analysis.Outcomes of allogeneic hematopoietic stem cell transplantation for lymphomas: a single-institution experience.Simplified validated prognostic model for progression-free survival after autologous transplantation for hodgkin lymphoma.HLA-haploidentical stem cell transplantation for hematologic malignancies.Optimal treatment for relapsing patients with Hodgkin lymphoma.Allogeneic transplantation for Hodgkin's lymphoma.Hematopoietic cell transplantation for lymphomas.Unrelated and alternative donor allogeneic stem cell transplant in patients with relapsed or refractory Hodgkin lymphoma: a systematic review.High-dose therapy followed by stem cell transplantation in Hodgkin's lymphoma: past and future.Managing Hodgkin lymphoma relapsing after autologous hematopoietic cell transplantation: a not-so-good cancer after all!Current role of autologous and allogeneic stem cell transplantation for relapsed and refractory hodgkin lymphoma.Salvage treatment for relapsed/refractory Hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents.Improving outcomes after allogeneic hematopoietic cell transplantation for Hodgkin lymphoma in the brentuximab vedotin era Umbilical cord blood transplantation in adults with advanced hodgkin's disease: high incidence of post-transplant lymphoproliferative disease.The role of hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma.Seven-year follow-up of allogeneic transplant using BCNU, etoposide, cytarabine and melphalan chemotherapy in patients with Hodgkin lymphoma after autograft failure: importance of minimal residual disease.Allogeneic haematopoietic stem-cell transplantation with reduced intensity conditioning for advanced stage Hodgkin's lymphoma in Sweden: high incidence of post transplant lymphoproliferative disorder.Next-generation sequencing-based detection of circulating tumour DNA After allogeneic stem cell transplantation for lymphoma.A prospective investigation of cell dose in single-unit umbilical cord blood transplantation for adults with high-risk hematologic malignancies.Long-term follow-up of allogeneic stem cell transplantation in relapsed/refractory Hodgkin lymphoma.Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR.Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphoma.Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial

P2860

Q26822480-C97F763F-114B-4602-9D57-EF6649F9B4CD Q33941128-50D90168-692F-4316-AB95-1B301AC31534 Q34044024-305A231E-3448-4E58-966B-CED77D64574A Q34145155-DCBEA016-F603-428D-9B31-382B1F7176FF Q34240314-3BAC8433-6E2E-41F5-958C-8A6EDD3BEED4 Q34296914-BA75AF31-CA81-4714-9F9F-4D26E3D8D659 Q35093521-3F3ED59F-18F6-48B3-9CF9-D3F2DC85498D Q35103536-6648E031-793F-4382-A6C5-F9BF71AE8497 Q35108791-9F7F38B2-7EFE-4C7F-9B3C-7426FCF9B241 Q35110765-97021386-100E-4C18-9904-030051E79A15 Q36166896-81421696-F96E-4ADC-9FF1-908203F42C0A Q37388718-8CA2D480-D9B5-4890-9E7A-849D0FE8502B Q37429226-02972114-E64F-47FB-B349-9C31F8757934 Q37530611-8DE0EF76-0D40-4957-9549-CBE2E0AAB471 Q37627991-CA0A667B-D199-4094-8CC7-A388D7C8DC2E Q37810094-D6342EA6-7550-414C-A036-9DB57754911C Q37820685-710FEDE6-5E62-4D00-A0B9-271F80BBEEEF Q37942817-5B1B2156-1F7B-4ADB-A93F-4D598428A818 Q38105131-56DD8541-0F2E-44E3-9851-5831FD205BC5 Q38132819-110CD081-99B3-45B4-B422-3BCBD5CF61DC Q38179975-588AEF3D-5A89-4655-9B13-5EE970511FDF Q38368587-F11FF843-E55F-4BEB-BC96-FC088D74CDFF Q38664909-9672CE59-8B44-497E-8E7D-523FC486443A Q38992200-03F4AE7B-18F8-4D20-93F9-55B2B1D394EB Q41353081-261E7B06-A2BC-42A1-A68B-949A7A39FDE9 Q43716206-A278D4D5-F71B-474A-86D7-95407F152026 Q44407363-251D774A-5676-4202-B404-B89C707F2A33 Q46734531-7AEBE177-9BB4-4521-83A9-CC838E52078A Q47603352-3C235E81-331C-4750-93BE-552406EAF40F Q48134193-ACD98B88-7802-4678-B039-DDFDC728CD95 Q48328423-9010EC1A-B70F-4B4D-AC02-76B3A06B27F1 Q50051516-64AE9470-43FE-4273-8DB0-AD153D2CA87D Q54686087-05BD2E16-D6FA-48A8-8921-44927F46136D Q56383260-2614423C-698B-4E62-8B23-56E04F904140

P2860

Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma.

http://www.wikidata.org/entity/Q34089534

description

2009 nî lūn-bûn

@nan

2009 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Unrelated donor reduced-intens ...... d refractory Hodgkin lymphoma.

@ast

Unrelated donor reduced-intens ...... d refractory Hodgkin lymphoma.

@en

Unrelated donor reduced-intens ...... d refractory Hodgkin lymphoma.

@nl

type

label

Unrelated donor reduced-intens ...... d refractory Hodgkin lymphoma.

@ast

Unrelated donor reduced-intens ...... d refractory Hodgkin lymphoma.

@en

Unrelated donor reduced-intens ...... d refractory Hodgkin lymphoma.

@nl

prefLabel

Unrelated donor reduced-intens ...... d refractory Hodgkin lymphoma.

@ast

Unrelated donor reduced-intens ...... d refractory Hodgkin lymphoma.

@en

Unrelated donor reduced-intens ...... d refractory Hodgkin lymphoma.

@nl

P1433

Q34089534-6B9A9DF8-19D4-4BFD-8A05-97DC0F807149

P1476

Q34089534-CCFFF03F-F025-4D11-A827-D492DDBC07F2

P2093

Q34089534-048C2C9D-8153-44E1-8850-ECB703DF0FA2

Q34089534-191B53D3-84C0-414E-A4FD-50261FDEF06C

Q34089534-21BAF97E-A09E-4B45-9AE7-BE5F7C3C9E5D

Q34089534-21C1B6B8-49D2-4171-8F4C-1CA1F5E6A159

Q34089534-338D44B0-597B-4FA4-A009-805313AFD4E3

Q34089534-55594067-6DEA-4D56-92AD-90609E3854D4

Q34089534-658A28A0-9F52-426B-9481-2F99486841E3

Q34089534-6CD003E9-6751-4ECC-BA28-0C4194BC5A05

Q34089534-764465E9-CC93-4ACC-99C9-3F9C3F1B1E54

Q34089534-932695B1-6C49-42AB-AF90-0F69B90AE31E

P2860

Q34089534-0BDE11D4-FBAC-4885-B647-C09BBDC795A6

Q34089534-1134639F-AFC1-4596-ABC0-DE68A554974C

Q34089534-18A56F6F-CF14-4FAE-BAFA-5DE352DC41FE

Q34089534-18C9CBA6-EAAE-4698-AC88-6A9DE44C56FD

Q34089534-19B1D669-5320-43E7-9513-66C2105BB673

Q34089534-1BA2AEF3-C9ED-4E6F-92F4-F7534DADB56E

Q34089534-340EA998-4645-49B1-8176-3613D5340620

Q34089534-3BA7D390-F0ED-4939-997B-33FFC885A972

Q34089534-3DCC67A2-63AF-4D6E-9F2B-573FF3CF2A59

Q34089534-44F909FB-C10D-4322-AA37-1E97A9E08888

P304

Q34089534-14426218-EBD7-44FC-B7C1-E8785159FEE4

P31

Q34089534-F51AF588-A489-4FD1-94C4-17933958A481

P356

Q34089534-AF2B10ED-F107-4185-9A48-EB48AA8D620C

P433

Q34089534-B6F0A43E-5D4A-4B4D-83E8-754E0088376F

P478

Q34089534-A2D55C22-E78D-44F4-AA0A-F37B786EC3A1

P50

Q34089534-158E349A-5487-4506-B0F3-841E0A523CC2

Q34089534-8AD43C69-F8F7-4F0B-BCD8-5A8254B788CC

Q34089534-B0CC051F-B33A-4324-AA50-64C69A86040B

P577

Q34089534-990F04B7-BAEE-4C0B-A1A9-FDCBBBCC9C36

P5875

Q34089534-BF1ED3F9-3AC2-4BD1-98BB-829A015BD16D

P698

Q34089534-F441FD0F-76A1-47C6-85D9-106FB599360C

P932

Q34089534-C68EC6A2-583D-49A8-92C8-28E015B70E34

P356

J.BBMT.2008.11.011

P1433

Biology of Blood and Marrow Transplantation

P1476

Unrelated donor reduced-intens ...... d refractory Hodgkin lymphoma.

@en

P2093

Brent R Logan

http://www.w3.org/2001/XMLSchema#string

Christopher N Bredeson

http://www.w3.org/2001/XMLSchema#string

César O Freytes

http://www.w3.org/2001/XMLSchema#string

David I Marks

http://www.w3.org/2001/XMLSchema#string

Jeanette Carreras

http://www.w3.org/2001/XMLSchema#string

John Gibson

http://www.w3.org/2001/XMLSchema#string

Koen van Besien

http://www.w3.org/2001/XMLSchema#string

Marcel P Devetten

http://www.w3.org/2001/XMLSchema#string

Paolo Anderlini

http://www.w3.org/2001/XMLSchema#string

Parameswaran N Hari

http://www.w3.org/2001/XMLSchema#string

P2860

Autologous hematopoietic cell transplantation in non-Hodgkin's lymphoma.

Non-myeloablative transplants for malignant disease.

Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial.

Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience.

High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation.

Immunosuppressive non-myeloablative allografting as salvage therapy in advanced Hodgkin's disease.

Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen.

Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors.

Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation.

High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: a multicenter study of the intergruppo Italiano Linfomi showing prolonged disease free survival in pat

P304

109-117

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.BBMT.2008.11.011

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P50

Robert Peter Gale

Hillard M Lazarus

P577

2009-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23770229

http://www.w3.org/2001/XMLSchema#string

P698

19135949

http://www.w3.org/2001/XMLSchema#string

P932

2929570

http://www.w3.org/2001/XMLSchema#string